ENTA up +1.66% percent right now. $ENTA High is at 44.80 and the Low 43.53 with current volume of 140,445.
Recent News posted below.
ENTA Enanta Pharmaceuticals Inc Recent Headline News
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.76 (+0.56), GILD: 106.67 (+0.22), CNAT: 7.02 (+0.17), MRK: 58.76 (-0.58), LGND: 54.82 (+0.88), RGLS: 20.94 (-1.14), ABBV: 63.64 (+2.14), BMY: 58.61 (+0.29), ENTA: 43.92 (+0.59)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.76 (+0.56), GILD: 106.67 (+0.22), CNAT: 7.02 (+0.17), MRK: 58.76 (-0.58), LGND: 54.82 (+0.88), RGLS: 20.94 (-1.14), ABBV: 63.64 (+2.14), BMY: 58.61 (+0.29), ENTA: 43.92 (+0.59)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.76 (+0.56), GILD: 106.68 (+0.23), CNAT: 7.02 (+0.17), MRK: 58.76 (-0.58), LGND: 54.82 (+0.88), RGLS: 20.94 (-1.14), ABBV: 63.64 (+2.14), BMY: 58.61 (+0.29), ENTA: 43.92 (+0.59)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.76 (+0.56), GILD: 106.68 (+0.23), ACHN: 12.78 (+2.67), CNAT: 7.02 (+0.17), MRK: 58.76 (-0.58), LGND: 54.82 (+0.88), RGLS: 20.94 (-1.14), ABBV: 63.64 (+2.14), BMY: 58.60 (+0.28), ENTA: 43.92 (+0.59)
Why AbbVie Inc.'s Game-Changing New Drug Could Be a Serious Threat to Gilead Sciences Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Nov 07, 7:45AM CST
The patent cliff might have decimated revenues in the world of Big Pharma, but it has also led to an unprecedented level of innovation within the industry. In the coming years, for example, we should see four to five new types of drugs that are...
JNJ: 108.76 (+0.56), ESRX: 77.88 (+0.01), GILD: 106.68 (+0.23), ABBV: 63.64 (+2.14), BMY: 58.60 (+0.28), ENTA: 43.92 (+0.59)
Enanta Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
Business Wire - Wed Nov 05, 3:05PM CST
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will make a formal corporate presentation on November 12, 2014 at 1:30 p.m. MT during the Credit Suisse 2014 Healthcare Conference.
ENTA: 43.92 (+0.59)
AbbVie Drops Shire Deal, Announces Buyback, Ups Dividend - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 3:32PM CDT
AbbVie Inc. (ABBV) has jointly agreed with Shire to terminate the planned acquisition of the latter, which was due to be completed by year end.
LCI: 51.89 (+1.72), SHPG: 200.91 (+2.33), ABBV: 63.64 (+2.14), ENTA: 43.92 (+0.59)
Nasdaq stocks posting largest percentage decreases
AP - Tue Oct 21, 12:44PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ASPS: 69.56 (-0.49), TKMR: 16.45 (-0.30), RMBS: 11.19 (+0.10), ENTA: 43.92 (+0.59), TKM.TO: 18.69 (-0.27), OMER: 17.36 (-0.01), INO: 11.16 (-0.07), SHOO: 32.50 (-0.05), RCII: 31.60 (+0.18), SCYX: 9.50 (+0.50), AMIC: 10.40 (-0.35), LAKE: 12.93 (-0.36), FBSS: 18.41 (-1.19)
Weak On High Volume: Enanta Pharmaceuticals (ENTA)
at The Street - Tue Oct 21, 9:03AM CDT
Trade-Ideas LLC identified Enanta Pharmaceuticals (ENTA) as a weak on high relative volume candidate
ENTA: 43.92 (+0.59)
Enanta (ENTA) Worth Watching: Stock Moves 6.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:41AM CDT
Enanta Pharmaceuticals (ENTA) was a big mover last session, with shares rising nearly 7% on the day.
MNK: 92.85 (+1.79), LCI: 51.88 (+1.71), CEMP: 13.82 (+0.06), ENTA: 43.92 (+0.59)
ImmunoGen (IMGN) in Focus: Stock Rallies 14% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 7:44AM CDT
ImmunoGen, Inc. (IMGN) was a big mover last session, as the company saw its shares surge nearly 14% on the day
LCI: 51.88 (+1.71), IMGN: 9.93 (+0.16), CEMP: 13.82 (+0.06), ENTA: 43.92 (+0.59)
Enanta Pharmaceuticals Provides Update on its Collaboration Agreement with AbbVie
Business Wire - Mon Oct 20, 3:52PM CDT
--Net Sales Allocations for ABT-450-Containing Regimens Finalized
ENTA: 43.92 (+0.59)
Nasdaq Extends Gains; Apple, Chipotle Rise Pre-Earnings
at Investor's Business Daily - Mon Oct 20, 12:21PM CDT
The S&P 500 and Nasdaq held on to decent gains in early afternoon trading Monday, undeterred by more weakness in Europe overnight. The Dow Jones industrial average couldn't keep up, however, weighed down by weak results from IBM (IBM) before the...
IBM: 163.76 (+1.69), AKRX: 35.78 (-0.81), CMG: 648.59 (-0.44), AFSI: 50.57 (+0.68), CP: 208.48 (+2.01), CSX: 36.43 (+0.98), ENTA: 43.92 (+0.59), AAPL: 108.92 (-0.09)
End Of The Year Events To Drive Some Of October's Beaten Up Biotech Companies
BMD Asset Management and Research - at Seeking Alpha - Mon Oct 20, 6:40AM CDT
JNJ: 108.76 (+0.56), NBIX: 18.90 (+0.32), GILD: 106.67 (+0.22), ALXN: 195.10 (+1.29), ABBV: 63.64 (+2.14), ENTA: 43.92 (+0.59), CELG: 107.88 (+1.43)
A Harvoni Vs. Olysio Price War Will Be Nonexistent: Consider Buying Gilead Now
BMD Asset Management and Research - at Seeking Alpha - Fri Oct 17, 12:54PM CDT
JNJ: 108.76 (+0.56), GILD: 106.68 (+0.23), MRK: 58.76 (-0.58), ABBV: 63.64 (+2.14), ENTA: 43.92 (+0.59)
ChemoCentryx, Inc. (CCXI) in Focus: Stock Rises 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 8:32AM CDT
ChemoCentryx, Inc. (CCXI) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
CCXI: 4.88 (+0.18), AMPE: 3.69 (-0.13), CEMP: 13.82 (+0.06), ENTA: 43.92 (+0.59)
Tetraphase (TTPH) Crumbles: Stock Tanks by 15% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:55AM CDT
Tetraphase has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
TTPH: 23.77 (-0.15), AMPE: 3.69 (-0.13), CEMP: 13.82 (+0.06), ENTA: 43.92 (+0.59)
TriNet And Enanta Shaping New Bases
at Investor's Business Daily - Wed Oct 15, 4:54PM CDT
Savvy investors know that market corrections can end suddenly and unexpectedly, and that maintaining a fresh watch list is key to capitalizing on the new opportunities. With the market correction deepening, investors should search for stocks that are...
ENTA: 43.92 (+0.59), TNET: 30.95 (+1.20)
Pacira (PCRX) Reveals Additional Safety Data on Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 4:45PM CDT
Pacira Pharmaceuticals, Inc. (PCRX) announced additional safety data from a comparative analysis on Exparel for peripheral nerve blocks.
LCI: 51.88 (+1.71), ACT: 245.11 (-0.80), ENTA: 43.92 (+0.59), PCRX: 87.87 (+1.85)
Why Is Sanofi Betting on MannKind Corporation's Afrezza?
George Budwell, The Motley Fool - Motley Fool - Mon Oct 06, 9:29AM CDT
Because the average cost of developing and bringing a new drug to market has now surpassed a whopping $5 billion, it has become commonplace for smaller pharmas to license out their first few approved products to larger companies with more resources,...
PFE: 30.21 (+0.29), LLY: 68.30 (+1.70), ABBV: 63.64 (+2.14), SNY: 46.33 (+0.64), MNKD: 5.86 (+0.08), ENTA: 43.92 (+0.59), ARNA: 4.37 (+0.11), NVS: 92.56 (+0.80)
Recent News posted below.
ENTA Enanta Pharmaceuticals Inc Recent Headline News
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.76 (+0.56), GILD: 106.67 (+0.22), CNAT: 7.02 (+0.17), MRK: 58.76 (-0.58), LGND: 54.82 (+0.88), RGLS: 20.94 (-1.14), ABBV: 63.64 (+2.14), BMY: 58.61 (+0.29), ENTA: 43.92 (+0.59)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.76 (+0.56), GILD: 106.67 (+0.22), CNAT: 7.02 (+0.17), MRK: 58.76 (-0.58), LGND: 54.82 (+0.88), RGLS: 20.94 (-1.14), ABBV: 63.64 (+2.14), BMY: 58.61 (+0.29), ENTA: 43.92 (+0.59)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.76 (+0.56), GILD: 106.68 (+0.23), CNAT: 7.02 (+0.17), MRK: 58.76 (-0.58), LGND: 54.82 (+0.88), RGLS: 20.94 (-1.14), ABBV: 63.64 (+2.14), BMY: 58.61 (+0.29), ENTA: 43.92 (+0.59)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.76 (+0.56), GILD: 106.68 (+0.23), ACHN: 12.78 (+2.67), CNAT: 7.02 (+0.17), MRK: 58.76 (-0.58), LGND: 54.82 (+0.88), RGLS: 20.94 (-1.14), ABBV: 63.64 (+2.14), BMY: 58.60 (+0.28), ENTA: 43.92 (+0.59)
Why AbbVie Inc.'s Game-Changing New Drug Could Be a Serious Threat to Gilead Sciences Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Nov 07, 7:45AM CST
The patent cliff might have decimated revenues in the world of Big Pharma, but it has also led to an unprecedented level of innovation within the industry. In the coming years, for example, we should see four to five new types of drugs that are...
JNJ: 108.76 (+0.56), ESRX: 77.88 (+0.01), GILD: 106.68 (+0.23), ABBV: 63.64 (+2.14), BMY: 58.60 (+0.28), ENTA: 43.92 (+0.59)
Enanta Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
Business Wire - Wed Nov 05, 3:05PM CST
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will make a formal corporate presentation on November 12, 2014 at 1:30 p.m. MT during the Credit Suisse 2014 Healthcare Conference.
ENTA: 43.92 (+0.59)
AbbVie Drops Shire Deal, Announces Buyback, Ups Dividend - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 3:32PM CDT
AbbVie Inc. (ABBV) has jointly agreed with Shire to terminate the planned acquisition of the latter, which was due to be completed by year end.
LCI: 51.89 (+1.72), SHPG: 200.91 (+2.33), ABBV: 63.64 (+2.14), ENTA: 43.92 (+0.59)
Nasdaq stocks posting largest percentage decreases
AP - Tue Oct 21, 12:44PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ASPS: 69.56 (-0.49), TKMR: 16.45 (-0.30), RMBS: 11.19 (+0.10), ENTA: 43.92 (+0.59), TKM.TO: 18.69 (-0.27), OMER: 17.36 (-0.01), INO: 11.16 (-0.07), SHOO: 32.50 (-0.05), RCII: 31.60 (+0.18), SCYX: 9.50 (+0.50), AMIC: 10.40 (-0.35), LAKE: 12.93 (-0.36), FBSS: 18.41 (-1.19)
Weak On High Volume: Enanta Pharmaceuticals (ENTA)
at The Street - Tue Oct 21, 9:03AM CDT
Trade-Ideas LLC identified Enanta Pharmaceuticals (ENTA) as a weak on high relative volume candidate
ENTA: 43.92 (+0.59)
Enanta (ENTA) Worth Watching: Stock Moves 6.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:41AM CDT
Enanta Pharmaceuticals (ENTA) was a big mover last session, with shares rising nearly 7% on the day.
MNK: 92.85 (+1.79), LCI: 51.88 (+1.71), CEMP: 13.82 (+0.06), ENTA: 43.92 (+0.59)
ImmunoGen (IMGN) in Focus: Stock Rallies 14% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 7:44AM CDT
ImmunoGen, Inc. (IMGN) was a big mover last session, as the company saw its shares surge nearly 14% on the day
LCI: 51.88 (+1.71), IMGN: 9.93 (+0.16), CEMP: 13.82 (+0.06), ENTA: 43.92 (+0.59)
Enanta Pharmaceuticals Provides Update on its Collaboration Agreement with AbbVie
Business Wire - Mon Oct 20, 3:52PM CDT
--Net Sales Allocations for ABT-450-Containing Regimens Finalized
ENTA: 43.92 (+0.59)
Nasdaq Extends Gains; Apple, Chipotle Rise Pre-Earnings
at Investor's Business Daily - Mon Oct 20, 12:21PM CDT
The S&P 500 and Nasdaq held on to decent gains in early afternoon trading Monday, undeterred by more weakness in Europe overnight. The Dow Jones industrial average couldn't keep up, however, weighed down by weak results from IBM (IBM) before the...
IBM: 163.76 (+1.69), AKRX: 35.78 (-0.81), CMG: 648.59 (-0.44), AFSI: 50.57 (+0.68), CP: 208.48 (+2.01), CSX: 36.43 (+0.98), ENTA: 43.92 (+0.59), AAPL: 108.92 (-0.09)
End Of The Year Events To Drive Some Of October's Beaten Up Biotech Companies
BMD Asset Management and Research - at Seeking Alpha - Mon Oct 20, 6:40AM CDT
JNJ: 108.76 (+0.56), NBIX: 18.90 (+0.32), GILD: 106.67 (+0.22), ALXN: 195.10 (+1.29), ABBV: 63.64 (+2.14), ENTA: 43.92 (+0.59), CELG: 107.88 (+1.43)
A Harvoni Vs. Olysio Price War Will Be Nonexistent: Consider Buying Gilead Now
BMD Asset Management and Research - at Seeking Alpha - Fri Oct 17, 12:54PM CDT
JNJ: 108.76 (+0.56), GILD: 106.68 (+0.23), MRK: 58.76 (-0.58), ABBV: 63.64 (+2.14), ENTA: 43.92 (+0.59)
ChemoCentryx, Inc. (CCXI) in Focus: Stock Rises 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 8:32AM CDT
ChemoCentryx, Inc. (CCXI) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
CCXI: 4.88 (+0.18), AMPE: 3.69 (-0.13), CEMP: 13.82 (+0.06), ENTA: 43.92 (+0.59)
Tetraphase (TTPH) Crumbles: Stock Tanks by 15% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:55AM CDT
Tetraphase has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
TTPH: 23.77 (-0.15), AMPE: 3.69 (-0.13), CEMP: 13.82 (+0.06), ENTA: 43.92 (+0.59)
TriNet And Enanta Shaping New Bases
at Investor's Business Daily - Wed Oct 15, 4:54PM CDT
Savvy investors know that market corrections can end suddenly and unexpectedly, and that maintaining a fresh watch list is key to capitalizing on the new opportunities. With the market correction deepening, investors should search for stocks that are...
ENTA: 43.92 (+0.59), TNET: 30.95 (+1.20)
Pacira (PCRX) Reveals Additional Safety Data on Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 4:45PM CDT
Pacira Pharmaceuticals, Inc. (PCRX) announced additional safety data from a comparative analysis on Exparel for peripheral nerve blocks.
LCI: 51.88 (+1.71), ACT: 245.11 (-0.80), ENTA: 43.92 (+0.59), PCRX: 87.87 (+1.85)
Why Is Sanofi Betting on MannKind Corporation's Afrezza?
George Budwell, The Motley Fool - Motley Fool - Mon Oct 06, 9:29AM CDT
Because the average cost of developing and bringing a new drug to market has now surpassed a whopping $5 billion, it has become commonplace for smaller pharmas to license out their first few approved products to larger companies with more resources,...
PFE: 30.21 (+0.29), LLY: 68.30 (+1.70), ABBV: 63.64 (+2.14), SNY: 46.33 (+0.64), MNKD: 5.86 (+0.08), ENTA: 43.92 (+0.59), ARNA: 4.37 (+0.11), NVS: 92.56 (+0.80)
